Skip to main
GMED

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 42%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical is a company with a strong 15+ year track record in developing and commercializing medical devices and solutions for patients with musculoskeletal disorders. With its recent acquisitions and offerings in the spine and interventional pain markets, the company is well-positioned for continued growth and expansion. Its strong execution, potential for high FCF and balance sheet optionality, and potential for multiple sources of upside make it an attractive investment opportunity with a positive outlook.

Bears say

Globus Medical is facing several risks, including a slowdown in spine market growth, potential revenue dis-synergies and disruption following recent mergers, lower sales in its Enabling Technologies segment, and the possibility of lower margins. These risks could negatively impact revenue growth and profitability, leading to a bear case scenario with revenue growth in the low-single digits and stagnant margins. This supports a price target of $84 per share, based on a P/E multiple of 18x the company's estimated 2027 adjusted EPS. This price target is in line with the company's peer group and average 4-year valuation, but significantly lower than the average for profitable MedTech companies with strong growth and high margin profiles, which typically trade at over 20x P/E.

Globus Medical (GMED) has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 42% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 12 analysts, Globus Medical (GMED) has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $99.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $99.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.